Connect with the future of healthcare
VB Devices is a company that develops and markets innovative devices for vascular medicine. Its products revolutionize current techniques, adding efficacy, safety and ease of use. Its flagship product, VARIXIO, launched in 2021, is becoming a worldwide reference product for the treatment of varicose veins, a disease that affects >25% of the population.
In the market
15.800.000€
2027
Medical devices
7%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
VB Devices is a Barcelona-based company that develops, manufactures and markets innovative medical devices for vascular medicine. It was founded in 2016 by vascular surgeon Enric Roche, and Federico Grego, an executive and entrepreneur with extensive experience in the biomedical sector, to provide solutions to unresolved clinical needs in the field of vascular interventions.
VB Devices’ business model is based on the development of innovative and patentable solutions, local outsourcing of manufacturing, and global marketing through a network of exclusive distributors.
The company is developing three product families, with the first two, VARIXIO and CRABCLAMP, having started commercialization in Europe in 2021.
Company portfolio
VARIXIO
Its main product, VARIXIO, is already used in more than 750 clinics and has the potential to become the reference product in the treatment of varicose veins, a disease that affects more than 25% of the population, and more than 50% of women over 50 years of age. The prevalence of this varicose veins translates into more than 10 million procedures per year, worldwide, and a market that exceeds $1.1 billion and is growing at an annual rate of 7%.
VARIXIO automates the preparation of sclerosing foam for the treatment of varicose veins with sclerotherapy, standardizing the procedure, adding efficacy, safety and convenience. Already today, sclerotherapy is the treatment of choice in more than 2/3 of varicose vein treatments worldwide. VARIXIO makes it possible to extend the applicability of this minimally invasive technique even further, making surgical intervention for varicose vein removal unnecessary in the vast majority of cases.
VARIXIO began direct marketing in Europe in 2021 through e-commerce, and today already has distribution contracts with specialized companies in more than 30 countries. VB Devices will have a turnover with VARIXIO of €293 thousand in 2021, €420 thousand in 2022, €550 thousand in 2023, and will approach €700 thousand in 2024.
CRABCLAMP+
CRABCLAMP+ is a simple and effective solution for keeping guidewires and catheters in place during endovascular procedures. This device avoids the risk of accidental loss of guidewires and contributes to the orderly maintenance of the surgical field, greatly facilitating complex procedures, such as aortic procedures, where multiple elements are used in the surgical field. This device, an evolution of the CRABCLAMP, offers greater versatility, allowing the fixation of guidewires, catheters, endolaser fibers and other devices. It facilitates the necessary rotation and mobility, providing freedom to the physician without compromising safety. It is ideal for both ICU and small team surgeries.
CRABCLAMP+ addresses a worldwide market of approximately 1.5 million procedures and, for now, there is no comparable solution.
The predecessor, CRABCLAMP, launched in January 2021, has been sold in more than 10 countries in Europe and Japan. We are currently in discussions with distributors and managing FDA approval for a U.S. launch in early 2025.
VARIXIO from VB Devices responds to the growing demand for varicose vein treatments, which have increased by 50% in the last 20 years. Although sclerotherapy is the most common and effective treatment, foam preparation remains a challenge that limits its scope. VARIXIO automates and standardises this process, making it more accessible for different types of veins, including smaller ones.
Already approved in the EU and other markets, VARIXIO has a strong commercial presence, and they are now looking to expand into the US market. Capital Cell sees VB Devices as an opportunity with great growth potential and a clear impact on improving vascular treatments.
VB Devices may face the challenge of reaching all physicians, especially those who are already accustomed to traditional sclerotherapy techniques. Although VARIXIO offers a more efficient and standardised solution, lack of exposure or training could limit its reach. This challenge in distribution and access to healthcare professionals could slow the company's growth as they seek to expand globally.
Already have an account? Please login here .
